Great Point Partners
Great Point Partners, established in 2003, is a Connecticut-based private equity firm that invests in healthcare companies across the United States, Canada, and Western Europe. The firm focuses on special situation, buyout, and growth equity investments, with a particular interest in pharma infrastructure services, healthcare IT-enabled services, medical devices, and other healthcare sectors. Great Point Partners is known for its long history of supporting executives in building successful healthcare companies, with an investment team augmented by CEO and Medical Advisory Boards. The firm typically invests in companies with EBITDA ranging from $1 to $10 million, and has raised multiple funds, including a $200 million fund in 2006.
Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of innovative therapies aimed at degrading disease-causing proteins. The company's lead product candidates include ARV-110, a proteolysis targeting chimera (PROTAC) currently in phase I clinical trials for metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. In addition to these, Arvinas is developing various other PROTACs aimed at degrading clinically relevant androgen receptor mutations and treatments for neurodegenerative diseases, including tauopathies. The company has established collaborations with prominent pharmaceutical firms such as Pfizer Inc., Genentech, and Bayer AG, enhancing its research capabilities and reach within the biopharmaceutical landscape. Founded in 2015, Arvinas aims to improve patient outcomes by eliminating harmful proteins from the body through its proprietary technology.
Biodel Inc. is a development-stage biopharmaceutical company based in Danbury, Connecticut, focused on creating treatments for diabetes. The company leverages its proprietary VIAdel technology to enhance the formulation of existing drugs, aiming to improve their efficacy and delivery. Biodel's lead product candidate is Linjeta, a rapid-acting mealtime insulin designed for individuals with Type I and Type II diabetes. In addition to Linjeta, the company is exploring earlier-stage candidates that include follow-on and second-generation rapid-acting insulins, a sublingual insulin tablet known as VIAtab, a line of basal insulins, and a glucagon formulation. Through its innovative approach, Biodel aims to address the needs of diabetes patients and improve their treatment options.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.